IDEXX Laboratories, Inc. (IDXX) News
Follow IDEXX Laboratories, Inc. (IDXX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 44 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
IDEXX Q3 Results Reflect Pricing Resilience Despite Lower Vet Visits, UBS Says
UBS said IDEXX Laboratories’ Q3 results reflected its ability to sustain robust pricing despite lower veterinary visits.
EQUITY | Nov 03, 2026, 05:05 PM UTC
M
ChemoMetec Raises Full-Year Outlook on Strong Demand, Lower Costs
The Danish company cited strong instrument demand and lower costs.
EARNINGS | Nov 03, 2026, 09:40 AM UTC
M
IDEXX Laboratories Reports Fiscal Q3 Profit
Profit attributable to shareholders rose 15.13% year over year; basic EPS was reported.
EQUITY | Nov 03, 2026, 04:49 AM UTC
M
IDEXX Laboratories Reports Third-Quarter 2026 Revenue of $1.21 Billion
Revenue rose 9.9% year over year to $1.21 billion. Net income increased 15.5% to $317.15 million and diluted EPS rose 17.9% to $4.01; organic revenue growth was 10%, led by companion animal diagnostics.
EQUITY | Nov 02, 2026, 09:31 PM UTC
M
Dow Rises in Choppy Session Amid US Election Anxiety
The Dow rose in a choppy session, with U.S. election anxiety cited in the headline.
EQUITY | Nov 02, 2026, 09:31 PM UTC
M
US Equity Indexes Rise as Crude Oil and Treasury Yields Fall
EQUITY | Nov 02, 2026, 07:22 PM UTC
M
Equities Rise Intraday Ahead of Midterm Elections as Oil Slides
MACRO | Nov 02, 2026, 07:00 PM UTC
M
Wall Street Rises as Oil Plunges More Than 6% on Iran War Hopes
Wall Street rose and oil fell more than 6% amid hopes for an end to the war in Iran.
MACRO | Nov 02, 2026, 06:35 PM UTC
M
Idexx Shares Rise 18% After Higher 3Q Results and Outlook Boost
Idexx Laboratories shares rose 18% to $651.88 on Monday after the company raised its outlook and reported higher profit and revenue in the latest quarter.
EARNINGS | Nov 02, 2026, 04:55 PM UTC
M
IDEXX Raises Forecast as Diagnostics Offset Weak Vet Visits
IDEXX raised its forecast, citing diagnostics as a potential offset to weak veterinary visits.
EARNINGS | Nov 02, 2026, 04:48 PM UTC
M
IDEXX Shares Rise 16.6% After Raising Annual Profit and Revenue Outlook
IDEXX Laboratories shares rose 16.6% after the company raised its annual profit and revenue expectations.
EQUITY | Nov 02, 2026, 03:58 PM UTC
M
IDEXX Laboratories raises annual profit and revenue outlook
IDEXX Laboratories raised its annual profit and revenue forecasts.
EQUITY | Nov 02, 2026, 03:58 PM UTC
M
IDEXX Shares Rise 19.4% After Forecasting FY Revenue Above Estimates
EARNINGS | Nov 02, 2026, 02:49 PM UTC
M
IDEXX Reports 10% Organic Revenue Growth in Q3 2026
IDEXX management cited diagnostics demand as the driver of 10% organic revenue growth in Q3 2026.
EQUITY | Nov 02, 2026, 02:33 PM UTC
M
IDEXX Executive Says Covet Revenue Run Rate Is About $20 Million
An IDEXX executive said Covet revenue is growing at strong double-digit rates.
EQUITY | Nov 02, 2026, 01:46 PM UTC
M
IDEXX lifts annual profit and revenue forecasts
Shares of veterinary diagnostics company IDEXX gained after it raised its annual profit and revenue forecasts.
EQUITY | Nov 02, 2026, 01:17 PM UTC
M
IDEXX Reports 10% Third-Quarter Revenue Growth and Raises 2026 Guidance
IDEXX reported third-quarter 2026 revenue of $1,214 million, up 10% on reported and organic bases. Earnings per diluted share rose 18% to $4.01; adjusted EPS was $3.96 and exceeded analyst expectations.
EQUITY | Nov 02, 2026, 12:32 PM UTC
M
IDEXX Shares Rise 6.5% Premarket After FY Revenue Forecast
IDEXX shares rose 6.5% premarket after the company forecast full-year revenue above estimates.
EARNINGS | Nov 02, 2026, 12:19 PM UTC
M
NAPCO Q1 Revenue Misses Estimates on Lower Distributor Purchases
NAPCO's first-quarter revenue missed estimates as distributor purchases declined.
EQUITY | Nov 02, 2026, 12:09 PM UTC
M
IDEXX Laboratories Announces Third-Quarter Results
EQUITY | Nov 02, 2026, 11:52 AM UTC
M
IDEXX Labs Raises 2026 Revenue View to $4.741B-$4.767B
EARNINGS | Nov 02, 2026, 11:45 AM UTC
M
IDEXX Q3 Revenue $1.214 Billion, Above IBES Estimate
IDEXX reported Q3 revenue of USD 1,214 million, compared with the IBES estimate of USD 1,191 million.
EQUITY | Nov 02, 2026, 11:45 AM UTC
M
IDEXX Q3 diluted EPS rises 18%; revenue increases 10%
EQUITY | Nov 02, 2026, 11:37 AM UTC
M
IDEXX Laboratories reports Q3 comparable EPS of $3.96
Q3 comparable EPS was $3.96, versus the FactSet estimate of $3.73.
EARNINGS | Nov 02, 2026, 11:34 AM UTC
M
IDEXX Q3 2026 Diluted EPS Rises 18%
IDEXX Laboratories said diluted earnings per share rose 18% in Q3 2026.
EARNINGS | Nov 02, 2026, 11:34 AM UTC
M
IDEXX Labs Reports Third-Quarter Revenue of $1.21 Billion
EQUITY | Nov 02, 2026, 11:32 AM UTC
M
IDEXX Labs Raises 2026 EPS View to $14.96–$15.16
EARNINGS | Nov 02, 2026, 11:32 AM UTC
M
IDEXX Q3 Gross Margin 62.9%
EARNINGS | Nov 02, 2026, 11:31 AM UTC
M
IDEXX Sets FY Revenue Outlook at USD 4,741-4,767 Million
IDEXX's FY revenue outlook is USD 4,741-4,767 million, versus an IBES estimate of USD 4,723 million.
EARNINGS | Nov 02, 2026, 11:31 AM UTC
L
IDEXX Reports Q3 EPS of USD 4.01
EARNINGS | Nov 02, 2026, 11:30 AM UTC
M
IDEXX Labs Reports Third-Quarter Net Income of $317.1 Million
EARNINGS | Nov 02, 2026, 11:30 AM UTC
M
IDEXX Laboratories Q3'26 Revenue Estimate Reported
IDEXX Laboratories is scheduled to report Q3'26 results on November 2 before the market opens. Revenue and EPS estimates were provided.
EQUITY | Oct 26, 2026, 11:00 AM UTC
M
IDEXX to Acquire CoVetAI for Veterinary AI Workflow Software
IDEXX Laboratories will acquire CoVetAI Inc., which provides AI-native ambient listening and clinical workflow software for veterinary practices. Financial terms were not disclosed.
EQUITY | Sep 16, 2026, 12:09 PM UTC
M
IDEXX Laboratories acquires CoVetAI
IDEXX Laboratories acquired CoVetAI to advance veterinary workflow intelligence.
EQUITY | Sep 16, 2026, 11:00 AM UTC
L
IDEXX director Kingsley Lawrence D sells $1,172,177 of common stock
Kingsley Lawrence D, an IDEXX Laboratories director, sold common stock on September 4, 2026. The shares were sold at a weighted average price of $532.0826 each for a reported total of $1,172,177.
EQUITY | Sep 09, 2026, 09:11 PM UTC
L
IDEXX Laboratories to participate in Morgan Stanley healthcare conference
IDEXX Laboratories announced participation in the Morgan Stanley 24th Annual Global Healthcare Conference.
EQUITY | Aug 31, 2026, 06:00 PM UTC
H
Why Is IDEXX Laboratories Stock Gaining Tuesday?
IDEXX Laboratories, Inc. (NASDAQ: IDXX ) stock rose Tuesday after the veterinary diagnostics company reported second-quarter results that topped Wall Street estimates and raised its full-year earnings outlook. Companion
EARNINGS | Aug 04, 2026, 03:39 PM UTC
H
IDEXX Laboratories Q2 2026 Earnings Call Transcript
IDEXX Laboratories (NASDAQ: IDXX ) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you APIs. For
EARNINGS | Aug 04, 2026, 01:35 PM UTC
H
IDEXX Reports Q2 Gross Margin 64%
IDEXX Q2 revenue beats estimates
EARNINGS | Aug 04, 2026, 10:44 AM UTC
H
IDXX - IDEXX Laboratories Announces Second Quarter Results
IDXX - IDEXX Laboratories Announces Second Quarter Results
EARNINGS | Aug 04, 2026, 10:40 AM UTC
H
IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 Est; Narrows FY2026 Sales Guidance from $4.
IDEXX Laboratories (NASDAQ: IDXX ) raises FY2026 GAAP EPS guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 analyst estimate. Narrows FY2026 sales outlook from $4.675 billion-$4.760 billion to $4.700 billion-$4.745
EARNINGS | Aug 04, 2026, 10:31 AM UTC
H
US Stocks: Implied EPS Movers
Multiple US stocks have implied EPS movers
EARNINGS | Aug 03, 2026, 06:15 PM UTC
L
BAH CNI FIX GSHD MRSH PSX RJF RNR SXT THC WRB AAL CHTR HAL HCA IDXX MCD MSFT MTDR ZTS PT changes @ UBS
BAH CNI FIX GSHD MRSH PSX RJF RNR SXT THC WRB AAL CHTR HAL HCA IDXX MCD MSFT MTDR ZTS PT changes @ UBS
EQUITY | Jul 27, 2026, 12:50 PM UTC
L
IDEXX Laboratories (IDXX) Looks Attractive on Recurring Revenue and High Customer Retention
IDEXX Laboratories (IDXX) Looks Attractive on Recurring Revenue and High Customer Retention
EQUITY | Jul 27, 2026, 12:09 PM UTC